When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...

Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...

In a surprising turn, obesity rates in the United States have decreased for the first time in more than a decade, according to a study published in the Journal of JAMA Health Forum. The study ...

In 14 states and the District of Columbia, Medicaid programs do not cover GLP-1s for obesity. Beneficiaries in these states, which include residents of New York, Illinois, and Ohio, can only access ...

The history of breakthrough weight loss medicines is riddled with tragic results. Based on the histories of phen-fen and ...

Researchers at Université de Montréal’s affiliated hospital research center (CRCHUM) suggest that targeting these molecules could offer new strategies to combat obesity. For years, Dr. Stephanie ...

In a first, scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known ... doctors prescribed it off-label for obesity, sparking a social media frenzy and supply ...